Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureHaiyan He, Zhongjun Xia, Fangbing Zhu, Baijun Fang, Wenming Chen, Yajun Li, Zhongxia Huang, Pengyun Zeng, Jianqing Mi, Zeping Zhou, Sujun Gao, Yaming Xi, Chunkang Chang, Shang-Yi Huang, Hao-Yuan Wang, Po-Shen Ko, Zonghong Shao, Jinwen Huang, Mingshen Dai, Tonghua Yang, Rong Zhan, Ming-Chung Wang, Suijing Wu
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
10.1016/s0140-6736(20)30734-0 · 2020
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
10.1016/s1470-2045(21)00128-5 · 2021
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
10.1056/nejmoa1607751 · 2016
Daratumumab, bortezomib, and dexamethasone for multiple myeloma
10.1056/nejmoa1606038 · 2016
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
10.1016/s0140-6736(21)00592-4 · 2021
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
10.1016/s0140-6736(19)32556-5 · 2019
Multiple myeloma
10.1038/s41572-024-00529-7 · 2024
Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
10.1056/nejmoa1817249 · 2019
Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial
10.1200/jco.22.00940 · 2023
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
10.1182/blood-2016-03-703439 · 2016
CD38 Antibodies in multiple myeloma: mechanisms of action and modes of resistance
10.3389/fimmu.2018.02134 · 2018
Infusion reactions associated with the medical application of monoclonal antibodies: the role of complement activation and possibility of inhibition by factor H
2018
Chromosome 1q21 abnormalities in multiple myeloma
10.1038/s41408-021-00474-8 · 2021
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
10.3324/haematol.2022.280660 · 2022
The importance of FISH signal cut-off value and copy number variation for 1q21 in newly diagnosed multiple myeloma: is it underestimated?
10.1016/j.clml.2022.01.013 · 2022
The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma
2021
Four-year follow-up of the phase 3 Pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in relapsed or refractory multiple myeloma (RRMM)
2019
Burden of multiple myeloma in China: an analysis of the Global Burden of Disease, Injuries, and Risk Factors Study 2019
10.1097/cm9.0000000000002600 · 2023
MOR202, a human anti-CD38 monoclonal antibody, mediates potent tumoricidal activity in vivo and shows synergistic efficacy in combination with different antineoplastic compounds
10.1182/blood.v126.23.3015.3015 · 2015
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
10.1016/s2352-3026(19)30249-2 · 2020
Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: updated analysis of LEPUS
10.1016/j.clml.2022.10.007 · 2023
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
10.1186/s13045-017-0501-4 · 2017
Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: a real-world cohort study in China
10.1002/cam4.7232 · 2024
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
10.1016/s2352-3026(20)30070-3 · 2020
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
10.1111/bjh.16292 · 2020
No additional external references are available.